Private Advisor Group LLC Sells 12,382 Shares of Celgene Corporation (CELG)
Private Advisor Group LLC decreased its position in Celgene Corporation (NASDAQ:CELG) by 12.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 85,198 shares of the biopharmaceutical company’s stock after selling 12,382 shares during the quarter. Private Advisor Group LLC’s holdings in Celgene Corporation were worth $11,239,000 at the end of the most recent quarter.
A number of other large investors have also recently modified their holdings of CELG. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in shares of Celgene Corporation during the first quarter worth approximately $118,000. Motco grew its position in shares of Celgene Corporation by 19.3% during the second quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 159 shares in the last quarter. Penserra Capital Management LLC acquired a new stake in shares of Celgene Corporation during the second quarter worth approximately $129,000. Acropolis Investment Management LLC acquired a new stake in shares of Celgene Corporation during the second quarter worth approximately $144,000. Finally, Mitsubishi UFJ Securities Holdings Co. Ltd. grew its position in shares of Celgene Corporation by 47.5% during the first quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 380 shares in the last quarter. 78.92% of the stock is owned by institutional investors.
Celgene Corporation (NASDAQ CELG) opened at $102.34 on Friday. The firm has a market capitalization of $80,574.02, a PE ratio of 15.99, a P/E/G ratio of 0.79 and a beta of 1.79. Celgene Corporation has a 12 month low of $94.55 and a 12 month high of $147.17. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52.
Celgene Corporation (NASDAQ:CELG) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.87 by $0.04. The firm had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. Celgene Corporation had a return on equity of 63.80% and a net margin of 27.36%. Celgene Corporation’s revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the business posted $1.58 EPS. analysts expect that Celgene Corporation will post 6.67 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This news story was first published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://www.watchlistnews.com/private-advisor-group-llc-sells-12382-shares-of-celgene-corporation-celg/1697264.html.
CELG has been the subject of a number of recent analyst reports. Leerink Swann reissued an “outperform” rating and set a $160.00 price target (up previously from $150.00) on shares of Celgene Corporation in a research report on Friday, July 28th. Oppenheimer Holdings, Inc. reissued a “buy” rating and set a $170.00 price target on shares of Celgene Corporation in a research report on Friday, October 20th. Vetr raised shares of Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $144.39 price target for the company in a research report on Monday, October 23rd. Cann reissued a “buy” rating on shares of Celgene Corporation in a research report on Thursday, October 26th. Finally, Morgan Stanley raised shares of Celgene Corporation from an “underweight” rating to an “equal weight” rating in a research report on Friday, October 27th. One analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have assigned a buy rating and two have assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $139.64.
In related news, insider Terrie Curran sold 1,727 shares of Celgene Corporation stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the transaction, the insider now owns 3,925 shares of the company’s stock, valued at approximately $564,768.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael D. Casey sold 9,250 shares of Celgene Corporation stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $139.03, for a total value of $1,286,027.50. Following the completion of the transaction, the director now directly owns 9,250 shares in the company, valued at approximately $1,286,027.50. The disclosure for this sale can be found here. Insiders sold a total of 20,227 shares of company stock worth $2,843,956 in the last three months. 0.95% of the stock is currently owned by company insiders.
Celgene Corporation Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.